Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Income from Continuing Operations (2016 - 2025)

Catalyst Pharmaceuticals' Income from Continuing Operations history spans 16 years, with the latest figure at 52698000.0 for Q4 2025.

  • For Q4 2025, Income from Continuing Operations rose 13.37% year-over-year to 52698000.0; the TTM value through Dec 2025 reached 214326000.0, up 38.78%, while the annual FY2025 figure was 214326000.0, 38.78% up from the prior year.
  • Income from Continuing Operations reached 52698000.0 in Q4 2025 per CPRX's latest filing, roughly flat from 52783000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 56737000.0 in Q1 2025 to a low of 30764000.0 in Q3 2023.
  • Average Income from Continuing Operations over 5 years is 28134550.0, with a median of 26421500.0 recorded in 2023.
  • Peak YoY movement for Income from Continuing Operations: surged 364.43% in 2022, then plummeted 235.24% in 2023.
  • A 5-year view of Income from Continuing Operations shows it stood at 9309000.0 in 2021, then soared by 364.43% to 43234000.0 in 2022, then plummeted by 60.59% to 17039000.0 in 2023, then soared by 172.8% to 46483000.0 in 2024, then rose by 13.37% to 52698000.0 in 2025.
  • Per Business Quant, the three most recent readings for CPRX's Income from Continuing Operations are 52698000.0 (Q4 2025), 52783000.0 (Q3 2025), and 52108000.0 (Q2 2025).